Abstract: In this invention, a non-infectious particle has been produced, comprising a pathogen antigen protein caused to be expressed on the surface of a virus particle having at least one species of paramyxovirus envelope protein missing from the particle. This particle has been found to hold within the particle a large amount of antigen protein compared to an infectious particle, and to be capable of eliciting a host immune response with extremely high efficiency. The non-infectious particle according to the present invention is useful as a vaccine against a pathogenic virus, or the like.
Type:
Grant
Filed:
November 17, 2017
Date of Patent:
August 31, 2021
Assignees:
Japan, as represented by the Director-General of National Institute of Infectious Disease, ID Pharma Co., Ltd.
Inventors:
Tetsuro Matano, Makoto Inoue, Hiroto Hara, Tsugumine Shu
Abstract: The present invention provides a virulent Pseudomonas fluorescens (P. fluorescens) phage ?Pf1901, and a phage ?Pf1901 preparation and an application thereof, and relates to the technical field of phage. The virulent P. fluorescens phage ?Pf1901 has an accession number of CCTCC M2019447. The virulent phage ?Pf1901 has a titer of (1.4-3)×1010 PFU/mL. The virulent phage ?Pf1901 has an optimal multiplicity of infection (MOI) value of 0.0001. The virulent P. fluorescens phage ?Pf1901 provided by the present invention exhibits very high specificity and lytic ability to P. fluorescens, which can be used to control P. fluorescens, with strong lytic and scavenging effects on a host.
Abstract: Embodiments include therapeutic peptides for preventing or reducing the transmission of a coronavirus such as SARS-CoV2. Also included are methods of using therapeutic peptides for reducing or preventing transmission of a coronavirus such as SARS-CoV2. The therapeutic peptides can prevent a region of the surface glycoprotein “spike” on SARS-CoV2 from interacting with angiotensin converting enzyme-2 (ACE-2) of host cells.
Abstract: Embodiments of the present invention relate to an infectious bronchitis virus (IBV) and an immunogenic composition comprising an IBV, respectively, wherein the ORF 3a and/or the ORF 3b and/or the ORF 5a and/or the ORF 5b is inactivated. Furthermore, aspects of the present invention relate to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, embodiments of the present invention relate to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the embodiments of the present invention.
Type:
Grant
Filed:
June 14, 2017
Date of Patent:
July 20, 2021
Inventors:
Petrus Rottier, Stefanus Van Beurden, Monique Verheije, Egbert Mundt
Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
Type:
Grant
Filed:
June 15, 2018
Date of Patent:
July 6, 2021
Assignee:
Novavax, Inc.
Inventors:
Peter M. Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
Abstract: This disclosure provides antibodies that are derived from CFR3022 and that can be administered to an individual that is infected with a virus. Antibodies herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies herein can be used to diagnose a SARS CoV 2 infection.
Type:
Grant
Filed:
May 14, 2020
Date of Patent:
June 15, 2021
Assignee:
Centivax, Inc.
Inventors:
Jacob Glanville, Shahrad Daraeikia, I-Chieh Wang, Sindy Andrea Liao Chan, Jean-Philippe Bürckert, Sawsan Youssef
Abstract: Amino acid sequences are provided that are directed against/and or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and therapeutic compounds and compositions provided by the invention show an improved stability, less immunogenicity and/or improved affinity and/or avidity for protein F of hRSV. The invention also relates to the uses of such amino acid sequences, polypeptides, compounds or constructs for prophylactic and/or therapeutic purposes.
Type:
Grant
Filed:
September 22, 2017
Date of Patent:
June 8, 2021
Assignee:
Ablynx N.V.
Inventors:
Erik Depla, Catelijne Stortelers, Stephanie Staelens
Abstract: This disclosure provides antibodies and antigen-binding fragments that are derived from 2ghw and that can be administered to an individual that is infected or suspected of being infected with a virus. Antibodies and antigen-binding fragments provided herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies and antigen-binding fragments provided herein can be used to diagnose a SARS-Cov-2 infection.
Type:
Grant
Filed:
May 14, 2020
Date of Patent:
June 1, 2021
Assignee:
Centivax, Inc.
Inventors:
Jacob Glanville, Shahrad Daraeikia, I-Chieh Wang, Sindy Andrea Liao-Chan, Jean-Philippe Bürckert, Sawsan Youssef
Abstract: Disclosed is cold-adapted live attenuated severe acute respiratory syndrome coronavirus (SARS-CoV-2) prepared by infecting cells with severe acute respiratory syndrome coronavirus and then adapting the severe acute respiratory syndrome coronavirus to a temperature from 37° C. to 22° C. in a step by step manner. Further, a vaccine containing the cold-adapted live attenuated severe acute respiratory syndrome coronavirus (SARS-CoV-2) is disclosed.
Type:
Grant
Filed:
October 26, 2020
Date of Patent:
June 1, 2021
Assignee:
The Industry & Academic Cooperation in Chungnam National University (IAC)
Abstract: This disclosure provides superhuman antibodies and antigen-binding fragments that can be administered to an individual that is infected or suspected of being infected with a virus. Superhuman antibodies and antigen-binding fragments provided herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to at least several weeks. Superhuman antibodies and antigen-binding fragments provided herein can be used to diagnose a SARS Cov-2 infection.
Type:
Grant
Filed:
May 14, 2020
Date of Patent:
June 1, 2021
Assignee:
Centivax, Inc.
Inventors:
Jacob Glanville, Shahrad Daraeikia, I-Chieh Wang, Sindy Andrea Liao-Chan
Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode an RSV immunogen are disclosed. Nucleic acids are disclosed that comprise the sequences that encodes consensus RSV F protein or immuno-genic fragment thereof, sequences that encodes an RSV G(A) protein or immunogenic fragment thereof and sequences that encodes an RSV G(B) protein or immunogenic fragment thereof. Compositions comprising one, combinations of two or all three sequences are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Nucleic acid molecules and compositions comprising the chemokine CC20 and/or a consensus RSV M2-1 protein or immunogenic fragment thereof are also disclosed. Immunomodulatory methods and methods of inducing an immune response against RSV are disclosed. Methods of preventing RSV infection and methods of treating individuals infected with RSV are disclosed.
Type:
Grant
Filed:
August 6, 2018
Date of Patent:
June 1, 2021
Assignee:
The Trustees of the University of Pennsylvania
Inventors:
David B. Weiner, Daniel Choo, Kar Muthumani, Nyamekye Obeng-Adjei, Veronica Scott
Abstract: The present specification relates to an anti-viral composition and, more particularly, to a composition that both is anti-viral and prevents and treats diseases associated with viruses, containing a peptide derived from a telomerase, thereby being effective in treating and preventing diseases associated with viruses and pathological symptoms caused by viruses. The peptide exhibits an effect of treating diseases associated with viruses by inhibiting the RNA replication of viruses, thereby being capable of providing a method that both is antiviral and prevents and treats diseases associated with viruses.
Abstract: Provided are a marker for detecting a highly pathogenic influenza virus including a protein mutant prepared by substituting the amino acids 68 and 69 of a PB1-F2 protein, a composition for detecting a highly pathogenic virus including an agent for measuring the protein mutant, and a detection kit including the same, a method for detecting a highly pathogenic virus including measuring the protein mutant, an antiviral composition against influenza A virus including an inhibitor of binding between a PB1-F2 protein in which the amino acids 68 and 69 are substituted and DDX3, and a method for screening an antiviral substance against influenza A virus.
Type:
Grant
Filed:
November 29, 2017
Date of Patent:
April 20, 2021
Assignee:
Dandi Bioscience Inc
Inventors:
Kyun-Hwan Kim, Eun Sook Park, Yeong-Min Park, Baik Lin Seong, Young Ho Byun, Hye Min Lee
Abstract: The invention relates to a genetically modified infectious measles virus derived from a live-attenuated measles virus strain, in which the gene encoding the viral accessory C protein has been knocked out (MV-deltaC). It concerns in particular the use of said genetically modified infectious MV-deltaC in the treatment of malignant tumour or cancer conditions, and for the preparation of agents or compositions for such treatment.
Type:
Grant
Filed:
June 3, 2019
Date of Patent:
April 20, 2021
Assignees:
INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE NANTES
Abstract: The invention provides, inter alia, improved replicons and vectors encoding them, where the replicons provide sustained expression of an encoded protein. These replicons comprise flavivirus replicases and heterologous protein coding sequences, wherein the heterologous protein coding sequences are flanked by separation sequences for improved efficacy. These nucleic acids provided by the invention, including self-replicating RNAs provided by the invention, are useful in methods of protein expression, such as for vaccines (e.g., for methods of immunization), as well as expression of therapeutic proteins, such as antibodies (e.g., for methods of treatment).
Type:
Grant
Filed:
February 25, 2016
Date of Patent:
April 13, 2021
Assignee:
Novartis AG
Inventors:
Caitlin Jeanette Hagen, Dong Yu, Peter W. Mason, Peter Shahinian
Abstract: The invention relates to pneumoviral virions comprising a viral genome that has a mutation in a gene coding for a protein that is essential for infectivity of the pneumovirus, whereby the mutation causes a virus produced from only the viral genome to lack infectivity, and whereby the virion comprises the protein in a form and in an amount that is required for infectivity of the virion. The invention also relates to methods for producing the pneumoviral virions and for using the virions in the treatment or prevention of pneumoviral infection and disease. A preferred pneumoviral virion is a virion of Respiratory Syncytial Virus in which preferably the gene for the G attachment protein is inactivated and complemented in trans.
Type:
Grant
Filed:
January 9, 2018
Date of Patent:
April 6, 2021
Assignee:
De Staat der Nederlanden, vert. door de minister van VWS
Inventors:
Willem Luytjes, Myra Noorely Widjojoatmodjo
Abstract: Described are stable pre-fusion respiratory syncitial virus (RSV) F polypeptides, immunogenic compositions comprising the polypeptides and uses thereof for the prevention and/or treatment of RSV infection.
Type:
Grant
Filed:
April 24, 2014
Date of Patent:
January 26, 2021
Assignee:
Janssen Vaccines & Prevention B.V.
Inventors:
Johannes Petrus Maria Langedijk, Anders Krarup